1081-50-1

Usage

Uses

Used in Organic Synthesis:
(2Z)-2-[(pyridin-4-ylcarbonyl)hydrazono]propanoic acid is used as a building block in organic synthesis for the creation of various complex organic molecules. Its hydrazono functional group allows for versatile chemical reactions, making it a valuable component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (2Z)-2-[(pyridin-4-ylcarbonyl)hydrazono]propanoic acid is used as a key intermediate in the development of new drugs. Its unique structure and potential biological activities make it a promising candidate for the treatment of various diseases and disorders. Researchers are actively exploring its potential as a therapeutic agent, particularly in the areas of oncology, infectious diseases, and neurological disorders.
Used as a Chemical Intermediate:
(2Z)-2-[(pyridin-4-ylcarbonyl)hydrazono]propanoic acid serves as an important chemical intermediate in the production of various specialty chemicals. Its versatility and reactivity make it a valuable precursor in the synthesis of dyes, pigments, and other functional materials.
Used in Medicinal Chemistry Research:
(2Z)-2-[(pyridin-4-ylcarbonyl)hydrazono]propanoic acid is a subject of interest in medicinal chemistry research due to its potential biological activities. Researchers are investigating its interactions with biological targets and evaluating its efficacy in various in vitro and in vivo models. (2Z)-2-[(pyridin-4-ylcarbonyl)hydrazono]propanoic acid's unique structure and properties make it a promising candidate for the development of novel therapeutic agents and drug delivery systems.

Upstream product

• 54-85-3 isoniazid 
• 127-17-3 2-oxo-propionic acid 

Relevant academic research and scientific papers

Synthesis and structural characterization of diorganotin(IV) esters with pyruvic acid isonicotinyl hydrazone and pyruvic acid salicylhydrazone Schiff bases

Eight diorganotin esters of Schiff base ligands formulated as [R 2SnLY]2, where L1 is 4-NC5H 4CON2C(CH3) CO2 with Y = H 2O, R = Ph (1), PhCH2 (2)

Design and synthesis of 2-(2-isonicotinoylhydrazineylidene)propanamides as InhA inhibitors with high antitubercular activity

Based on successful antitubercular isoniazid scaffold we have designed its “mee-too” analogues by a combination of this drug linked with substituted anilines through pyruvic acid as a bridge. Lipophilicity important for passive diffusion through impenetrable mycobacterial cell wall was increased by halogen substitution on the aniline. We prepared twenty new 2-(2-isonicotinoylhydrazineylidene)propanamides that were assayed against susceptible Mycobacterium tuberculosis H37Rv, nontuberculous mycobacteria, and also multidrug-resistant tuberculous strains (MDR-TB). All the compounds showed excellent activity not only against Mtb. (minimum inhibitory concentrations, MIC, from ≤0.03 μM), but also against M. kansasii (MIC ≥2 μM). The most active molecules have CF3 and OCF3 substituent in the position 4 on the aniline ring. MIC against MDR-TB were from 8 μM. The most effective derivatives were used for the mechanism of action investigation. The treatment of Mtb. H37Ra with tested compounds led to decreased production of mycolic acids and the strains overproducing InhA were more resistant to them. These results confirm that studied compounds inhibit the enoyl-acyl carrier protein reductase (InhA) in mycobacteria. The compounds did not show any cytotoxic and cytostatic activity for HepG2 cells. The amides can be considered as a promising scaffold for antitubercular drug discovery having better antimicrobial properties than original isoniazid together with a significantly improved pharmaco-toxicological profile.

Design and synthesis of highly active antimycobacterial mutual esters of 2-(2-isonicotinoylhydrazineylidene)propanoic acid

The combination of two active scaffolds into one molecule represents a proven approach in drug design to overcome microbial drug resistance. We designed and synthesized more lipophilic esters of 2-(2-isonicotinoylhydrazineylidene)propanoic acid, obtained from antitubercular drug isoni-azid, with various alcohols, phenols and thiols, including several drugs, using carbodiimide-mediated coupling. Nineteen new esters were evaluated as potential antimycobacterial agents against drug-sensitive Mycobacterium tuberculosis (Mtb.) H37 Rv, Mycobacterium avium and Mycobacterium kansasii. Selected derivatives were also tested for inhibition of multidrug-resistant (MDR) Mtb., and their mechanism of action was investigated. The esters exhibited high activity against Mtb. (minimum inhibitory concentrations, MIC, from ≤0.125 μM), M. kansasii, M. avium as well as MDR strains (MIC from 0.25, 32 and 8 μM, respectively). The most active mutual derivatives were derived from 4-chloro/phenoxy-phenols, triclosan, quinolin-8-ol, naphthols and terpene alcohols. The experiments identified enoyl-acyl carrier protein reductase (InhA), and thus mycobacterial cell wall biosynthesis, as the main target of the molecules that are activated by KatG, but for some compounds can also be expected adjunctive mechanism(s). Generally, the mutual esters have also avoided cytotoxicity and are promising hits for the discovery of antimycobacterial drugs with improved properties compared to parent isoniazid.

Self-assembly of organotin(IV) moieties with the Schiff-base ligands pyruvic acid isonicotinyl hydrazone and pyruvic acid salicylhydrazone: Synthesis, characterization, and crystal structures of monomeric or polymeric complexes

A series of organotin(IV) complexes of the type [R2SnLY] 2 or [R2SnL(R3SnOH)]2 [L = 4-NC 5H4CON2C(CH3)CO2 or 2-HOC6H4CONsu